• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Hong Kong·Healthcare·8158.HK
Share

China Regenerative Medicine International Limited Stocks

HK$ 0.32Last Updated 24.06.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

HK$ 12.43M

HK$ 0.32
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

China Regenerative Medicine International Limited operates as an investment holding entity, focusing on the development and distribution of a diverse portfolio of healthcare products and associated services. The company provides extensive health management solutions, covering health condition assessments, detoxification programs, fostering internal bodily balance, nourishing vital organs, and enhancing the immune system. Additionally, its beauty offerings encompass non-surgical medical aesthetics, essential dermatological care, anti-aging skin remedies, hair revitalization, skin firming treatments, localized body contouring, and intimate restoration services. Established in 1995, the organization was previously known as China Bio-Med Regeneration Technology Limited until its rebranding to China Regenerative Medicine International Limited in March 2015. Its headquarters are situated in Tsim Sha Tsui, Hong Kong.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is 'cheap' on P/E, overvalued on EV/EBITDA, over

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

26.06.2026 07:30

"Even the iPhone won't escape this": What is Wall Street saying about Apple's price hikes?

26.06.2026 03:02

Bain has revised its forecast for luxury market growth downward. Why is it talking about a recovery in the industry?

26.06.2026 01:29

Market Split: Nasdaq Falls for the Fourth Consecutive Day Despite a Rally in Chipmakers

26.06.2026 00:48

Qualcomm will produce AI chips for Meta's data centers. Its stock soared

26.06.2026 00:13

Citigroup raised its price target for SanDisk by 23%. Its stock has already risen 860% in 2026

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026